Brickell Biotech announced Wednesday that it is rebranding to Fresh Tracks Therapeutics.
Fresh Tracks introduced its new name, logo, website and branding elements to reflect the company’s “evolution into a clinical-stage pharmaceutical company” set on disrupting existing treatment options.
The company seeks to develop differentiated prescription therapeutics to treat autoimmune, inflammatory and other debilitating diseases.
“We believe the name Fresh Tracks Therapeutics captures the essence of our mission to develop groundbreaking, novel therapies that have the potential to restore immune balance,” Fresh Tracks CEO Robert Brown said in a statement.
The Colorado-based company’s stock will begin trading under a new Nasdaq ticker symbol on Thursday.
Fresh Tracks also unveiled its newly formed Scientific Advisory Board, which features five scientists with expertise in the fields of immunology and inflammation.